By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech firm HemoShear today announced a $4.3 million Phase II Small Business Innovation Research grant to profile the effects of 50 known drugs on the human blood vessel system using the company's proprietary human vascular surrogate system.

The grant, the third received by the Charlottesville, Va.-based company in the past two years, is from the National Heart, Lung, and Blood Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.